COVID-19 Hastalığında Antisitokin Tedaviler
Özet
COVID-19 enfeksiyonunda gelişen ve mortalitenin ana nedenlerinden biri olan sitokin fırtınası sendromuna yönelik antisitokin ve immünomodülatör tedaviler, kontrollü bir inflamatuar yanıt oluşturmak amacıyla klinik ağırlığa göre uygulanmaktadır. Solunum yetmezliği ve oksijen gereksinimi olan ağır veya kritik vakalarda, bağışıklık sistemini baskılayarak organ hasarını önleyen deksametazon gibi sistemik kortikosteroidlerin kullanımı mortaliteyi azaltmada kritik öneme sahiptir. İnflamasyon belirteçleri yüksek seyreden hastalarda kortikosteroid tedavisine ek olarak tosilizumab veya sarilumab gibi proinflamatuar interlökin-6 (IL-6) inhibitörlerinin ya da alternatif olarak baricitinib ve tofasitinib gibi Janus Kinaz (JAK) inhibitörlerinin kombinasyon şeklinde erken dönemde başlanması olumlu klinik sonuçlar vermektedir. Epitel hasarı sonrasında salınan IL-1'i hedefleyen anakinra ve canakinumab gibi inhibitörlerin etkinliği araştırılmaya devam ederken; kolşisin, standart intravenöz immünoglobulin (IVIG) ve GM-CSF inhibitörlerinin rutin kullanımı mevcut kılavuzlarca önerilmemektedir. Bu medikal tedavilerin yanı sıra, plazma değişimi ve hemoperfüzyon gibi ekstrakorporeal kan saflaştırma yöntemleri de kandaki inflamatuar medyatörleri uzaklaştırarak sitokin fırtınasını yönetmede etkilidir. Sonuç olarak, aşırı inflamasyonu viral replikasyonu artırmadan baskılamak adına, antisitokin tedavilerinin doğru zamanlamayla ve hasta komorbiditelerine göre seçilmesi hayati değer taşımaktadır.
The COVID-19 infection, which exhibits a heterogeneous course, can trigger a cytokine storm and acute respiratory distress syndrome (ARDS) in severe cases, making early anti-inflammatory and anticytokine interventions vital for reducing mortality. Systemic corticosteroids, particularly dexamethasone, are strongly recommended for severe or critical patients requiring oxygen support, as they suppress excessive inflammation and preserve organ functions when administered at the correct clinical timing. For patients demonstrating rapid systemic inflammation, combining corticosteroids with interleukin-6 (IL-6) inhibitors like tocilizumab or sarilumab, or alternatively utilizing Janus kinase (JAK) inhibitors such as baricitinib, significantly optimizes survival rates and improves clinical outcomes. While specific interleukin-1 (IL-1) blockers like anakinra are being investigated, routine applications of colchicine, intravenous immunoglobulins (IVIG), and GM-CSF inhibitors lack sufficient supportive evidence in standard guidelines. Beyond pharmacotherapy, extracorporeal blood purification methods—including therapeutic plasma exchange and hemoperfusion filters authorized for emergency use—play a crucial role in mitigating severe hyperinflammation by directly adsorbing circulating cytokines from the bloodstream. Ultimately, tailoring the precise initiation of these immunomodulatory strategies based on respiratory requirements, localized guidelines, and patient specific comorbidities remains essential to prevent secondary infections while successfully calming the hyperinflammatory cascade.
Referanslar
1.Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. [cited 2022 Feb 2]; Available from: https://doi.org/10.1007/s10067-020-05190-5
2.Adarsh Bhimraj A, Morgan RL, Hirsch Shumaker A, Lavergne V, Baden L, Chi-Chung Cheng V, et al. Last updated February 3, 2022 and posted online at www.idsociety.org/COVID19guidelines. Please check website for most updated version of these guidelines. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. [cited 2022 Feb 16]; Available from: www.idsociety.org/COVID19guidelines.
Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC, et al. Surviving Sepsis Campaign Guidelines on the Management of Adults with Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med [Internet]. 2021 [cited 2022 Feb 6];E219–34. Available from: https://journals.lww.com/ccmjournal/Fulltext/2021/03000/Surviving_Sepsis_Campaign_Guidelines_on_the.21.aspx
Organization WH. Who Published_Guideline_5999-9_2. WHO Ref number WHO/2019-nCoV/therapeutics/20221 [Internet]. Available from: https://files.magicapp.org/guideline/8d102c12-6858-4dfe-ab34-bb8639c158ab/published_guideline_5999-9_2.pdf
England JT, Abdulla A, Biggs CM, Lee AYY, Hay KA, Hoiland RL, et al. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. Blood Rev [Internet]. 2021 Jan 1 [cited 2022 Feb 5];45:100707. Available from: /pmc/articles/PMC7227559/
Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med [Internet]. 2020 Dec 3 [cited 2022 Jan 23];383(23):2255. Available from: /pmc/articles/PMC7727315/
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet [Internet]. 2020 Mar 28 [cited 2022 Feb 7];395(10229):1033–4. Available from: http://www.thelancet.com/article/S0140673620306280/fulltext
Danışma B, Çalışması K. ANTİSİTOKİN-ANTİİNFLAMATUAR TEDAVİLER, KOAGÜLOPATİ YÖNETİMİ.
Ombrello MJ, Schulert GS. COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome? Transl Res [Internet]. 2021 Jun 1 [cited 2022 Feb 8];232:1. Available from: /pmc/articles/PMC7934701/
10.Yongzhi X. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue. Emerg Microbes Infect [Internet]. 2021 [cited 2022 Feb 5];10(1):266. Available from: /pmc/articles/PMC7894425/
11.Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol [Internet]. 2021 Jan 1 [cited 2022 Feb 5];93(1):250–6. Available from: https://pubmed.ncbi.nlm.nih.gov/32592501/
12.Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol [Internet]. 2020 Jun 16 [cited 2022 Jan 23];11. Available from: https://pubmed.ncbi.nlm.nih.gov/32612617/
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect [Internet]. 2020 Jun 1 [cited 2022 Jan 23];80(6):607. Available from: /pmc/articles/PMC7194613/
Cappanera S, Palumbo M, Kwan SH, Priante G, Martella LA, Saraca LM, et al. When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It. J Clin Med 2021, Vol 10, Page 297 [Internet]. 2021 Jan 15 [cited 2022 Feb 7];10(2):297. Available from: https://www.mdpi.com/2077-0383/10/2/297/htm
15.Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev [Internet]. 2020 Jun 1 [cited 2022 Feb 3];53:66. Available from: /pmc/articles/PMC7204669/
16.Soleimani A, Taba SMM, Hasibi Taheri S, Loghman AH, Shayestehpour M. The effect of hemoperfusion on the outcome, clinical and laboratory findings of patients with severe COVID-19: a retrospective study. New Microbes New Infect. 2021 Nov 1;44:100937.
17.Mehta P, Fajgenbaum DC. Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. Curr Opin Rheumatol [Internet]. 2021 Sep 1 [cited 2022 Feb 7];33(5):419. Available from: /pmc/articles/PMC8373392/
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol [Internet]. 2020 May 1 [cited 2022 Feb 25];214:108393. Available from: /pmc/articles/PMC7102614/
COVID-19 Treatment Guidelines 2.
Cron RQ, Caricchio R, Chatham WW. Calming the cytokine storm in COVID-19. Nat Med 2021 2710 [Internet]. 2021 Sep 3 [cited 2022 Feb 7];27(10):1674–5. Available from: https://www.nature.com/articles/s41591-021-01500-9
Sterne JAC, Murthy S, Diaz J V., Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA [Internet]. 2020 Oct 6 [cited 2022 Feb 6];324(13):1330–41. Available from: https://jamanetwork.com/journals/jama/fullarticle/2770279
Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med [Internet]. 2021 Feb 25 [cited 2022 Feb 6];384(8):693–704. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2021436
Group TCS 2 T, Russell L, Uhre KR, Lindgaard ALS, Degn JF, Wetterslev M, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA [Internet]. 2021 Nov 9 [cited 2022 Feb 6];326(18):1807–17. Available from: https://jamanetwork.com/journals/jama/fullarticle/2785529
Table: Characteristics of Immunomodulators | COVID-19 Treatment Guidelines [Internet]. [cited 2022 Feb 10]. Available from: https://www.covid19treatmentguidelines.nih.gov/tables/immunomodulators-characteristics/
Hospitalized Adults: Therapeutic Management | COVID-19 Treatment Guidelines [Internet]. [cited 2022 Feb 14]. Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/
Corticosteroids | COVID-19 Treatment Guidelines [Internet]. [cited 2022 Feb 10]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/
Interleukin-6 Inhibitors | COVID-19 Treatment Guidelines [Internet]. [cited 2022 Feb 11]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-6-inhibitors/
Group TWREA for C-19 T (REACT) W, Domingo P, Mur I, Mateo GM, Gutierrez M del M, Pomar V, et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA [Internet]. 2021 Aug 10 [cited 2022 Feb 10];326(6):499–518. Available from: https://jamanetwork.com/journals/jama/fullarticle/2781880
Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P, et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med [Internet]. 2021 Jan 1 [cited 2022 Feb 10];181(1):32–40. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772187
Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med [Internet]. 2021 Jan 7 [cited 2022 Feb 10];384(1):20–30. Available from: https://pubmed.ncbi.nlm.nih.gov/33332779/
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med [Internet]. 2020 Dec 10 [cited 2022 Feb 10];383(24):2333–44. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2028836
Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet [Internet]. 2021 May 1 [cited 2022 Feb 10];397(10285):1637–45. Available from: http://www.thelancet.com/article/S0140673621006760/fulltext
33.Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19 | FDA [Internet]. [cited 2022 Feb 11]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19
34.Sanford Guide [Internet]. [cited 2022 Feb 17]. Available from: https://webedition.sanfordguide.com/en/drug-information/antiviral-agents/coronavirus/tocilivumab
35.Kinase Inhibitors | COVID-19 Treatment Guidelines [Internet]. [cited 2022 Feb 15]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/kinase-inhibitors/
36.Uzunçakmak Tk, Bayazit S, Serdaroğlu S. Dermatolojide Janus Kinaz İnhibitörleri. Türkiye Klin Dermatoloji - Özel Konular [Internet]. 2021 [cited 2022 Feb 15];14(1):91–101. Available from: https://www.turkiyeklinikleri.com/article/tr-dermatolojide-janus-kinaz-inhibitorleri-93069.html
Asgharpour M, Mehdinezhad H, Bayani M, Zavareh MSH, Hamidi SH, Akbari R, et al. Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19). BMC Nephrol [Internet]. 2020 Aug 20 [cited 2022 Jan 23];21(1). Available from: /pmc/articles/PMC7439633/
38.Gao YM, Xu G, Wang B, Liu BC. Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J Intern Med [Internet]. 2021 Feb 1 [cited 2022 Jan 23];289(2):147–61. Available from: /pmc/articles/PMC7404514/
39.Kaçar CK, Uzundere O, Kandemir D, Yektaş A. Efficacy of HA330 Hemoperfusion Adsorbent in Patients Followed in the Intensive Care Unit for Septic Shock and Acute Kidney Injury and Treated with Continuous Venovenous Hemodiafiltration as Renal Replacement Therapy. Blood Purif [Internet]. 2020 Jul 1 [cited 2022 Jan 23];49(4):448–56. Available from: https://www.karger.com/Article/FullText/505565
40.Monard C, Rimmelé T, Ronco C. Extracorporeal Blood Purification Therapies for Sepsis. Blood Purif [Internet]. 2019 Apr 1 [cited 2022 Jan 23];47(Suppl3):2–15. Available from: https://www.karger.com/Article/FullText/499520
41.Safari S, Salimi A, Zali A, Jahangirifard A, Bastanhagh E, Aminnejad R, et al. Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review. Arch Acad Emerg Med [Internet]. 2020 [cited 2022 Jan 23];8(1):67. Available from: http://journals.sbmu.ac.ir/aaem
42.Honoré PM, De Bels D, Barreto Gutierrez L, Spapen HD. Hemoadsorption therapy in the critically ill: solid base but clinical haze. Ann Intensive Care [Internet]. [cited 2022 Jan 23]; Available from: https://doi.org/10.1186/s13613-019-0491-1
Administration D. FDA Combating COVID-19 With Medical Devices.
